Use of VM-26 as a single agent in the treatment of renal carcinoma.
VM-26 was administered to 13 patients with metastatic adenocarcinoma of the kidney. Twelve of the 13 patients were assessable. The remaining patient was nonevaluable due to early death as defined in the protocol. No responses were observed in any of the 12 patients. Nonhematological toxicity was mild except for one instance of life-threatening hypotension, occurring during the infusion of VM-26. Significant leukopenia (less than 3000/mm3) occurred in 29% of courses and significant thrombocytopenia (less than 100,000/mm3) occurred in 14% of courses. Further studies using VM-26 in renal cell carcinoma do not seem warranted.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D000368:Aged; D001853:Bone Marrow / Q000187:drug effects; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D013713:Teniposide / Q000009:adverse effects / Q000627:therapeutic use*
D013713:Teniposide; D011034:Podophyllotoxin